**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62346

**Manuscript Type:** CASE REPORT

**2+0 *CYP21A2* deletion carrier — a limitation of the genetic testing and counseling: A case report**

Xi N *et al.* 2+0 *CYP21A2* deletion carrier and CAH

Na Xi, Xiao Song, Xue-Yan Wang, Sheng-Fang Qin, Guan-Nan He, Ling-Ling Sun, Xi-Min Chen

**Na Xi, Xiao Song, Xue-Yan Wang, Sheng-Fang Qin, Ling-Ling Sun, Xi-Min Chen,** Department of Medical Genetics and Prenatal Diagnosis, Sichuan Provincial Hospital for Women and Children, Chengdu 610045, Sichuan Province, China

**Guan-Nan He,** Department of Ultrasound, Sichuan Provincial Hospital for Women and Children, Chengdu 610045, Sichuan Province, China

**Author contributions:** Xi N is responsible for the study conception and design, definition of intellectual content, literature research, clinical studies, data acquisition and analysis, statistical analysis, manuscript preparation and editing; Song X and He GN are responsible for the clinical studies, data acquisition; Wang XY is responsible for the integrity of the entire study, study conception and design, definition of intellectual content, clinical studies, data acquisition and manuscript review; Qin SF and Chen XM are responsible for the experimental studies; Sun LL is responsible for the clinical studies; all authors read and approved the final manuscript.

**Supported by** the Fundamental Research Funds of Health Commission of Sichuan Province, No. 17ZD035.

**Correspondence to: Xue-Yan Wang, MD,** Department of Medical Genetics and Prenatal Diagnosis, Sichuan Provincial Hospital for Women and Children, No. 290 Shayanxi Er Street, Wuhou District, Chengdu 610045, Sichuan Province, China. wang\_xueyan20@21cn.com

**Received:** January 7, 2021

**Revised:** March 4, 2021

**Accepted:** June 28, 2021

**Published online:**

**Abstract**

BACKGROUND

*CYP21A2* gene mutations may all cause reduction or loss of 21-hydroxylase activity, leading to development of congenital adrenal hyperplasia (CAH) with different clinical phenotypes. For families with CAH children, genetic testing of the parents and genetic counseling are recommended to assess the risk of recurrence.

CASE SUMMARY

We report a case of CAH with a high suspicion before delivery. The risk of the child suffering from CAH during the pregnancy had been underestimated due to the deviation of genetic counseling and genetic testing results. Our report confirmed a *CYP21A2* homozygous deletion in this case, *CYP21A2* heterozygous deletion in the mother, and a rare 2+0 *CYP21A2* deletion in the father.

CONCLUSION

It is important to analyze the distribution of *CYP21A2* gene in the two alleles of parents of children with CAH.

**Key Words:** *CYP21A2* gene mutations; Congenital adrenal hyperplasia; Pregnancy; Genetic counseling; Genetic testing; Pathogenic point mutations; Alleles

Xi N, Song X, Wang XY, Qin SF, He GN, Sun LL, Chen XM. 2+0 *CYP21A2* deletion carrier — a limitation of the genetic testing and counseling: A case report. *World J Clin Cases* 2021; In press

**Core Tip:** This study suggests that carriers of type 2+0 are likely to be a trap in genetic testing and genetic counseling.

**INTRODUCTION**

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive genetic diseases caused by adrenocortical hormone synthesis disorders[1]. Enzyme deficiencies involving adrenocortical hormone synthesis disorders include 21-hydroxylase deficiency (21-OHD), 11-β OHD, 17-OHD, 3β-hydroxy steroid dehydrogenase deficiency and 18-OHD, of which 21-OHD is the most common type and is the cause of > 90% of CAH cases[2]. Deficiency of enzymes leads to corticosteroid synthesis disorders, accumulation of precursor substances, increase in androgen bypass metabolites, adrenocorticotropic hormone secretion, and adrenal hypertrophy[3]. Depending on the extent of 21-OHD, it is divided into classic and nonclassical type, in which the former includes salt loss type and simple masculine type[4]. According to previous reports, the incidence of classic CAH is around 1:5000-1:15000 due to ethnic differences[5]. The gene encoding 21-hydroxylase is *CYP21A2*. Gene mutations including substitutions, deletions and point mutations may all cause the reduction or loss of enzyme activity, leading to the development of CAH with different clinical phenotypes. For families with CAH children, genetic testing of the parents and genetic counseling are recommended to assess the risk of recurrence.

We report a case of CAH with a high suspicion before delivery and confirmed diagnosis after delivery. The risk of the child suffering from CAH during the pregnancy was underestimated due to the deviation of genetic counseling on his brother (who died after birth) and the father’s genetic test results. The genetic test confirmed that the case carried a *CYP21A2* homozygous deletion, the mother carried a *CYP21A2* heterozygous deletion, and the father carried a rare 2+0 *CYP21A2* deletion.

**CASE PRESENTATION**

***Chief complaints***

A 30-year-old pregnant woman came to our prenatal diagnosis center for consultation at 26 wk of pregnancy. During this pregnancy, the mother only accepted routine obstetric examination procedures. She came to our center for consultation because she had concerns and hoped to receive a detailed prenatal diagnosis through color Doppler ultrasound examination.

***History of present illness***

The patient had a free present medical history.

***History of past illness***

The patient was pregnant for the second time and gave birth to the first child, a boy, in the hospital 19 mo ago. No special circumstances occurred during delivery. More than 10 d later, the newborn was referred to a superior hospital because of severe choking on milk, crying, and restlessness. Further examination revealed that the boy had electrolyte disturbances (hyperkalemia and hyponatremia), multiple organ damage (renal insufficiency, myocardial damage and brain damage), metabolic acidosis, moderate dehydration, and undescended bilateral testicles. Diagnosis of CAH, newborn pneumonia or neonatal sepsis was then considered. Unfortunately, the child died after rescue failed.

***Personal and family history***

The *CYP21A2* gene of the patient’s first dead child and his parents was detected by multiplex ligation-dependent probe amplification (MLPA), polymerase chain reaction (PCR) and Sanger sequencing and found a heterozygous deletion of *CYP21A2* gene exons 1-7 that was inherited from the mother. At the same time, there were multiple pathogenic point mutations in the *CYP21A2* gene and these mutations did not come from the father. Based on the results of this genetic testing, the pregnant woman was told that these point mutations in the child were new. Although the mother is a carrier of *CYP21A2* gene deletion, the father is not. Thus, the probability of having CAH offspring is very low.

***Physical examination***

No physical examination was done at the center in this study.

***Laboratory examinations***

Because of the abnormal findings on color Doppler ultrasound examination, combined with the medical history of pregnant women who have had a child with CAH, we recommended amniocentesis for gender diagnosis and *CYP21A2* genetic testing. After consultation with the pregnant woman and her family, the proposal for amniocentesis was rejected.

***Imaging examinations***

At 27+5 wk of pregnancy, the woman underwent color Doppler ultrasound examination that revealed enlarged fetal bilateral adrenal glands, abnormal genital morphology, and ambiguous gender (Figure 1). The patient asked for color Doppler ultrasound examination again at 32 wk of pregnancy. The 32 wk color Doppler ultrasound result still suggested that the shape of the external fetal genitalia was blurred and the bilateral adrenal glands were enlarged.

**FINAL DIAGNOSIS**

Subsequent diagnosis of the pregnant woman was done at other institutions and not provided to this study.

**TREATMENT**

Subsequent treatment of the pregnant woman was done at other institutions and not provided to this study.

**OUTCOME AND FOLLOW-UP**

After 5 wk, the pregnant woman gave birth to a newborn with abnormal genitalia, difficult to distinguish sex, increased body hair, and thick hair on the head and face. The newborn died after rescue failure due to electrolyte disturbance and multiple organ damage. Fluorescence *in situ* hybridization showed that the gender of the newborn was female without aneuploidy detected by the probe.

Having given birth to two CAH children, the parents required more detailed genetic testing. The *CYP21A2* gene of the neonate, parents and grandparents was tested using the SALSA MLPA P050 kit from MBC-Holland of the Netherlands (Figure 2) and showed a homozygous deletion of the *CYP21A2* gene in the newborn and a heterozygous deletion in the mother. The deletion and pathogenic point mutation of the *CYP21A2* gene were not found in the father. However, the heterozygous deletion of the *CYP21A2* gene was found in the grandfather and *CYP21A2* gene duplication in the grandmother.

Deoxyribonucleic acid (DNA) high-throughput sequencing technology, Gerber’s self-developed detection method and PGXCloud system 2.7.5, PGD analysis software 2.0 were used to identify the single nucleotide polymorphism site in the family *CYP21A2* gene (NM\_000500.7 chr6: 32006093-32009447 forward transcription) and adjacent regions and found that the two alleles of the child were from the father and mother, and the two alleles of the father were from the grandfather and grandmother of the child.

**DISCUSSION**

The highly homologous pseudogene *CYP21A1P* is closely linked to *CYP21A2*. The gene *CYP21A2*, pseudogene *CYP21A1P*, three other genes *RP1*, *C4* and *TNXB*, and two pseudogenes *RP2* and *TNXA* together form a genetic unit called the RCCX module[6,7]. Both *CYP21A2* functional genes and pseudogenes contain 10 exons, and the nucleotide sequence homology between exons is up to 98%. The nucleotide sequence homology between introns is as high as 96%[6,8]. Although pseudogenes do not encode functional proteins, their high sequence homology with functional genes brings major challenges to genetic testing. The MLPA and gene sequencing results of the children of this family showed a homozygous deletion of the *CYP21A2* gene, and the reason for the deletion is presumed to be pseudogene recombination. The fetal and maternal MLPA test results confirmed that she was a carrier of a *CYP21A2* single copy deletion, which was also speculated to be pseudogene recombination. The father’s test results showed no copy number deletion or pathogenic point mutation of the *CYP21A2* gene. Based on this family, two consecutive CAH children with similar phenotypes were born, which is inconsistent with the genetic principle. We speculate the following four possibilities: (1) new mutation; (2) paternal gonad mosaicism; (3) patient was maternal uniparental disomy (UPD); and (4) father had a *CYP21A2* gene duplication in one haplotype, and the other haplotype *CYP21A2* gene was recombined by pseudogenes, which was 2+0 type.

For speculation on the pathogenicity of new mutations, the genetic test results of the first child in this family found a heterozygous deletion of a large fragment of *CYP21A2* and multiple pathogenic point mutations. Although the technical details and original documents of the current genetic testing are no longer available, we speculate that it may be that the amplification product was interfered with by pseudogenes due to primer design or the control of the experimental system. The subsequent sequencing results revealed the multiple pathogenic point mutations, which were not new mutations of the functional gene, but a false-positive test result. Large-scale sequencing found that the average new mutation rate of the human genome is 1.20 × 10-8 per generation, and 1 or 2 are generally present in the coding region[9]. Therefore, the probability of multiple new point mutations on a single gene is extremely low. Approximately 1% of the pathogenic variants of *CYP21A2* come from new mutations[10]. As a result, the possibility that *CYP21* mutations in both the child and the elder brother come from *de novo* mutations is even below (1.20 × 10-8)2. Considering that the *de novo* mutations in exon regions are rarer and low-frequency pathogenic *CYP21* mutations come from *de novo* mutations, this possibility is even much lower and can be basically ruled out.

Also, due to the low incidence of UPD, the likelihood of maternal UPD in 2 consecutive children is low. Because we failed to collect the father’s sperm samples, we cannot completely rule out the assumption of a high proportion of chimeras in the father’s gonads. However, based on the rule of embryonic development and previous studies on chimerism in monogenic diseases, there is a low probability of a high proportion of chimerism in a single organ, and chimeric signals are generally found in organs with multiple tissue sources[11]. From our blood-based MLPA and haplotype sequencing results, we did not see a clear chimeric signal and therefore we speculate that this possibility is also low.

One hypothesis we are most interested in is that the father is a 2+0 type carrier. There are reports of *CYP21A2* duplication haplotypes, and the incidence of this haplotype is sometimes equal to or even higher than the population carrying rate of the classic pathogenic mutation of the *CYP21A2* gene[12-14], suggesting the possibility of 2+0 pathogenicity. According to a previously published method for *SMN1* gene 2+0 carriers[15], we conducted MLPA testing on the grandparents of the children and found that the grandfather was a carrier of a single deletion due to pseudogene recombination. The grandmother of the child had 3 copies of the *CYP21A2* gene. To further understand the status of chromatids in pedigree inheritance and exclude the possibility of maternal UPD, we did haplotype analysis of pedigree members. The results confirmed 2 *CYP21A2* deleted alleles; 1 from the mother and 1 from the father. The 2 alleles of the child’s father also came from the child’s grandfather and grandmother. Comprehensive testing found that that the grandmother was type 2+1, the grandfather was type 1+0, and the father inherited a haplotype from the grandmother’s *CYP21A2* duplication and the grandfather’s haplotype with *CYP21A2* gene copy number deletion to form the 2+0 type.

The 2 alleles of the brother and the child were inherited from the parents and were recombined by the pseudogene and the *CYP21A2* gene deletion type allele. This confirms our hypothesis about the genetic test results of the brothers: false positives caused by the pseudogenes interference with sequencing results (Figure 3).

Genetic counseling for the family is important and necessary to help the family cope with this hard time and deciding whether or not to get pregnant in the future. Thus, we organized a group discussion with the family to let the guardian of the child know about this situation. To keep them fully informed, the group included a representative from the laboratory that performed the genetic testing, a genetic counselor, and the primary care provider. We also suggested a group discussion with the family in future research if a similar situation occurs.

To our knowledge, this is the first report of a 2+0 silent *CYP21A2* deletion carrier. Previous studies have found a *CYP21A2* duplication haplotype combined with another *CYP21A2* deleted haplotype in patients with CAH salt loss. In the *CYP21A2* duplication haplotypes, both copies of *CYP21A2* carry severe pathogenic variants[13,14]. The haplotype frequency of *CYP21A2* duplication is 1.6%–3.5%. Most of the haplotypes of *CYP21A2* duplication have one *CYP21A2* gene carrying the Q318X mutation. No 2+0 carriers were found in non-CAH populations[13,14,16,17].

This report implies that current quantitative copy number variation (CNV) detection methods such as PCR and MLPA have some limitations to detect silent carriers of pathological genetic disorders, such as gene duplication paired with gene loss on the opposite chromosome or allele (2+0) in this report. MLPA has been regarded as the gold standard for CNV determination. Furthermore, laboratories worldwide commonly rely on MLPA for the diagnosis and research of genetic disorders[18]. Nevertheless, MLPA is limited to analyzing the distribution in the two alleles and has a risk of missed detection of 2/0 carriers. For example, Alías *et al*[15] tested 1562 individuals to determine their SMA carrier status using MLPA, while the exclusive use of such a quantitative detection method of only independent individuals in a given family led to failure in identifying carrier status. In their study, all blood relatives characterized as 2/0 carriers were identified by studying their respective parents, but not by MLPA.

The situation is similar for the PCR test method. The protocol is based on long-range PCR amplification with allele-specific primers, followed by DNA sequencing. PCR together with the Sanger sequencing is a robust testing strategy aiming to determine whether a point mutation or indel exists[19]. However, pathological genetic disorders, such as gene duplication paired with gene loss on the opposite chromosome or allele (2+0) may be missed using PCR sequencing testing. In addition, *CYP21A2* has a duplicated pseudogene called *CYP21A1P* and they share 98% and 96% sequence homology in exons and in noncoding regions. All the reasons above make the definition of the 2+0 carrier in this report more complicated.

**CONCLUSION**

This study suggests that carriers of type 2+0 are likely to be a limitation of genetic testing and counseling. The father of the child was interpreted as a non-CAH carrier in a previous genetic testing report, which caused the risk of recurrent CAH to be erroneously underestimated by genetic counseling. This pregnancy did not have opportunities for earlier corresponding genetic testing for the fetus or intrauterine intervention. These results reveal that there are some limitations of the current testing strategy to detect silent carriers of pathological genetic disorders, such as gene duplication paired with gene loss on the opposite chromosome or allele (2+0). Thus, only detecting the CNV in the *CYP21A2* gene with current detection methods is not sufficient. For couples who have had children with CAH, in addition to routine detection of the copy number of the *CYP21A2* gene and pathogenic point mutations, it is also important to analyze the distribution of the *CYP21A2* gene in the two alleles.

**REFERENCES**

1 **Krone N**, Arlt W. Genetics of congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab* 2009; **23**: 181-192 [PMID: 19500762 DOI: 10.1016/j.beem.2008.10.014]

2 **Speiser PW**, White PC. Congenital adrenal hyperplasia. *N Engl J Med* 2003; **349**: 776-788 [PMID: 12930931 DOI: 10.1056/NEJMra021561]

3 **Wedell A**. An update on the molecular genetics of congenital adrenal hyperplasia: diagnostic and therapeutic aspects. *J Pediatr Endocrinol Metab* 1998; **11**: 581-589 [PMID: 9829208 DOI: 10.1515/jpem.1998.11.5.581]

4 **White PC**, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocr Rev* 2000; **21**: 245-291 [PMID: 10857554 DOI: 10.1210/edrv.21.3.0398]

5 **Thil'en A**, Nordenström A, Hagenfeldt L, von Döbeln U, Guthenberg C, Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. *Pediatrics* 1998; **101**: E11 [PMID: 9521977 DOI: 10.1542/peds.101.4.e11]

6 **Higashi Y**, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. *Proc Natl Acad Sci U S A* 1986; **83**: 2841-2845 [PMID: 3486422 DOI: 10.1073/pnas.83.9.2841]

7 **Yang Z**, Mendoza AR, Welch TR, Zipf WB, Yu CY. Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations. *J Biol Chem* 1999; **274**: 12147-12156 [PMID: 10207042 DOI: 10.1074/jbc.274.17.12147]

8 **White PC**, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. *Proc Natl Acad Sci U S A* 1986; **83**: 5111-5115 [PMID: 3487786 DOI: 10.1073/pnas.83.14.5111]

9 **Kong A**, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, Gudjonsson SA, Sigurdsson A, Jonasdottir A, Jonasdottir A, Wong WS, Sigurdsson G, Walters GB, Steinberg S, Helgason H, Thorleifsson G, Gudbjartsson DF, Helgason A, Magnusson OT, Thorsteinsdottir U, Stefansson K. Rate of de novo mutations and the importance of father's age to disease risk. *Nature* 2012; **488**: 471-475 [PMID: 22914163 DOI: 10.1038/nature11396]

10 **Krone N**, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. *J Clin Endocrinol Metab* 2000; **85**: 1059-1065 [PMID: 10720040 DOI: 10.1210/jcem.85.3.6441]

11 **Yang X**, Liu A, Xu X, Yang X, Zeng Q, Ye AY, Yu Z, Wang S, Huang AY, Wu X, Wu Q, Wei L, Zhang Y. Genomic mosaicism in paternal sperm and multiple parental tissues in a Dravet syndrome cohort. *Sci Rep* 2017; **7**: 15677 [PMID: 29142202 DOI: 10.1038/s41598-017-15814-7]

12 **Bachega TA**, Billerbeck AE, Madureira G, Arnhold IJ, Medeiros MA, Marcondes JA, Longui CA, Nicolau W, Bloise W, Mendonca BB. Low frequency of CYP2B deletions in Brazilian patients with congenital adrenal hyperplasia due to 21-hydroxylas deficiency. *Hum Hered* 1999; **49**: 9-14 [PMID: 10189236 DOI: 10.1159/000022833]

13 **Koppens PF**, Hoogenboezem T, Degenhart HJ. Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. *Hum Genet* 2002; **111**: 405-410 [PMID: 12384784 DOI: 10.1007/s00439-002-0810-7]

14 **Koppens PF**, Hoogenboezem T, Halley DJ, Barendse CA, Oostenbrink AJ, Degenhart HJ. Family studies of the steroid 21-hydroxylase and complement C4 genes define 11 haplotypes in classical congenital adrenal hyperplasia in The Netherlands. *Eur J Pediatr* 1992; **151**: 885-892 [PMID: 1473541 DOI: 10.1007/BF01954123]

15 **Alías L**, Barceló MJ, Bernal S, Martínez-Hernández R, Also-Rallo E, Vázquez C, Santana A, Millán JM, Baiget M, Tizzano EF. Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene. *Clin Genet* 2014; **85**: 470-475 [PMID: 23799925 DOI: 10.1111/cge.12222]

16 **Parajes S**, Quinteiro C, Domínguez F, Loidi L. High frequency of copy number variations and sequence variants at CYP21A2 Locus: implication for the genetic diagnosis of 21-hydroxylase deficiency. *PLoS One* 2008; **3**: e2138 [PMID: 18478071 DOI: 10.1371/journal.pone.0002138]

17 **Witchel SF**. Congenital Adrenal Hyperplasia. *J Pediatr Adolesc Gynecol* 2017; **30**: 520-534 [PMID: 28450075 DOI: 10.1016/j.jpag.2017.04.001]

18 **Bashton M**, Hollis R, Ryan S, Schwab CJ, Moppett J, Harrison CJ, Moorman AV, Enshaei A. Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia. *Sci Rep* 2020; **10**: 45 [PMID: 31913349 DOI: 10.1038/s41598-019-56972-0]

19 **Maremonti E**, Brede DA, Olsen AK, Eide DM, Berg ES. Ionizing radiation, genotoxic stress, and mitochondrial DNA copy-number variation in Caenorhabditis elegans: droplet digital PCR analysis. *Mutat Res* 2020; **858-860**: 503277 [PMID: 33198926 DOI: 10.1016/j.mrgentox.2020.503277]

**Footnotes**

**Informed consent statement:** Informed consent was obtained.

**Conflict-of-interest statement:** There are no potential conflicts of interest to disclose.

**CARE Checklist (2016) statement:** The article was revised according to the journal guide.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 7, 2021

**First decision:** February 12, 2021

**Article in press:**

**Specialty type:** Geriatrics and gerontology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Jelski W, Wang R **S-Editor:** Zhang L **L-Editor:** Filipodia **P-Editor:**


**Figure Legends**



**Figure 1 A color Doppler ultrasound examination.** A: The downward arrow refers to the enlarged labia majora, which is easily mistaken for an empty scrotum. The arrow to the left refers to the labia minora, which is easily mistaken for a penis; B: Enlarged left adrenal gland; C: Enlarged right adrenal gland.



**Figure 2 Standard operating instructions.** A: Results of multiplex ligation-dependent probe amplification (MLPA) in children; B: MLPA result of the father of the child; C: MLPA results of the mother; D: MLPA result of the grandfather; and E: MLPA result of the grandmother.



**Figure 3 Scheme of the genetic testing.**